# A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

Study · id `cardio:ct-nct06268873` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06268873](<https://clinicaltrials.gov/study/NCT06268873>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06268873

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 2554 participants.

## Technical summary

Registry record NCT06268873. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-29 (actual); primary completion 2028-02-24 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2554 participants (enrolled count; ClinicalTrials.gov record NCT06268873, source copy `cardio:ctgov-nct06268873-2026-06-26`, retrieved 2026-10-26)
- Started: 2024-03-29 (actual) (ClinicalTrials.gov record NCT06268873, source copy `cardio:ctgov-nct06268873-2026-06-26`, retrieved 2026-10-26)
- Primary completion: 2028-02-24 (anticipated) (ClinicalTrials.gov record NCT06268873, source copy `cardio:ctgov-nct06268873-2026-06-26`, retrieved 2026-10-26)
- Completion: 2028-02-24 (anticipated) (ClinicalTrials.gov record NCT06268873, source copy `cardio:ctgov-nct06268873-2026-06-26`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Chile; China; Czechia; Denmark; France; Germany; Greece; Hungary; India; Israel; Italy; Japan; Malaysia; Netherlands; Peru; Philippines; Poland; Romania; Saudi Arabia; Serbia; Slovakia; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; Türkiye; Ukraine; United Kingdom; Vietnam (ClinicalTrials.gov record NCT06268873, source copy `cardio:ctgov-nct06268873-2026-06-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06268873-2026-06-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
- Condition: Chronic Kidney Disease and Hypertension
- Intervention (Drug): Baxdrostat/dapagliflozin
- Intervention (Drug): Dapagliflozin in combination with placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 205a5bfe82bce6b102cfcefe916da6b23e1a895b0384cf0f1dfff9086c15f89a
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
